UroLift for the Treatment of Lower Urinary Tract Symptoms in a Patient with AMS 700 MS Implanted Penile Prosthesis. The First Reported Case in the Literature
Main Article Content
Abstract
The UroLift system (Teleflex Inc.) is a minimally-invasive and non-ablative technique used for the treatment of male lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia. It has been introduced as an alternative to transurethral resection of the prostate (TURP) to avoid any unwanted side affects such as erectile dysfunction, hospital stay and catheterisation. A 68-year old patient with bothersome LUTS and significant co-morbidities presented for consideration of UroLift to avoid the risks associated with more invasive TURP surgery. The patient had previously had an AMS 700 MS implanted penile prosthesis (IPP) inserted for erectile dysfunction refractory to medical therapy. To the authors best knowledge, there have been no reports or published literature on the use of the UroLift device to treat male LUTS in the presence of an IPP. This case report aims to present this unique case and discuss operative technique for use of the UroLift device in the presence of an IPP.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of articles published in all DPG titles is retained by the author(s). The author(s) grants DPG the rights to publish the article and identify itself as the original publisher. The author grants DPG exclusive commercial rights to the article. The author grants any party the rights to use the article freely for non-commercial purposes provided that the original work is properly cited.
References
2. National Institute for Health and Care Excellence. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG26). http://nice.org.uk/guidance/mtg26. Published 16.09.2015.
3. British Association of Urological Surgeons. Prostatic urethral lift (UroLift) implant. September 2017. https://www.baus.org.uk/_userfiles/pages/files/Patients/Leaflets/Urolift.pdf
4. Kirby RS, Kirby M, Fitzpatrick JM. Benign prostatic hyperplasia: counting the cost of its management. BJU Int. 2010; 105:901-902.
5. Mishriki SF, Grimsley SJ, Nabi G et al. Improved quality of life and enhanved satisfaction after TURP: prospective 12-year follow-up study. Urology. 2008; 72: 322-326.
6. Ahyai S, Gilling P, Kaplan S et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. European Association of Urology 2010; 58: 384-97.
7. British Association of Urological Surgeons (BAUS). Transurethral Prostatectomy (TURP) for benign disease – information about your procedure from BAUS (Internet). Available from:
8. Ray A, Morgan H, Wilkes A et al. The UroLift system for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A NICE medical technology guidance. Appl Health Econ Health Policy (2016) 14; 515-526.
9. Bardoli AD, Taylor WST, Mahmalji W. Can the UroLift prostatic implant device treat the symptoms of benign prostatic hypertrophy, avoid sexual dysfunction and reduce hospital TURP waiting times? A single centre, single surgeon experience and review of the literature. The Aging Male, 2017 (online).
10. Bardoli AD, Taylor WST, Cobley J et al. Is there a minimally invasive day case operation to treat LUTS secondary to BPH and avoid sexual dysfunction? UroLift a case report. Journal of Men’s Health, 2017 Vol 14 (1):e1-e3.
11. Roehrborn CG, Barkin J, Gange SN et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T study. Can J Urol; 2017; 24 (3): 8802-8813.
12. Munir A, Kalsi J, Nazareth I et al. Erectile dysfunction. BMJ 2014; 348: g129.
13. Demir O, Akgul K, Akar Z et al. Association between lower urinary tract symptoms and sexual dysfunction assessed using the core lower urinary tract symptom score and International Index of Erectile Function-5 questionnaires. Aging Male. 2012; 15: 111-114.
14. Feldman HA, Johannes CB, Derby CA et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Preventitive medicine, 2000; Apr, 30(4): 328-38.
15. Rajendran R, Cummings M. Erectile dysfunction: assessment and management in primary care. Prescribing in practice. 2014; 25-30.
16. Khera M. Erectile dysfunction. BMJ Clin Evid. 2011; 2011:1803.
17. Hatzimouratidis K, Earldey I Giuliano F et al. EAU guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation. European association of urology 2014. https://uroweb.org/wp-content/uploads/14-Male-Sexual-Dysfunction_LR.pdf
18. Castiglione F, Ralph D, Muneer A. Surgical techniques for managing post-prostatectomy erectile dysfunction. Curr Urol Rep. 2017; 18(11):90
19. Scott FB, Bradley WE, Timm GW. Management of erectile impotence. Use of implantable prosthesis. Urology 1973; 2:80-2.
20. Knoll D, Henry G, Culkin D et al. Physician and patient satisfaction with the new AMS 700 momentary squeeze inflatable penile prosthesis. J Sex Med 2009; 6:1773-1778.
21. Wilson SK, Ckeves MA, Delk JR. Ulter cylinders: problems with uncontrolled lengthening (the S-shape deformity). J Urol 1996;155:135-137.
22. Wang R, Howard GE, Hoang A et al. Prospective and long-term evaluation of erect penile length obtained with inflatable penile prosthesis to that induced by intracavernosal injection. Asian J Androl 2009;11:411-5.
23. Negro CL, Paradiso M, Rocca A et al. Implantation of AMS 700 LGX penile prosthesis preserves penile length without the need for penile lengthening procedures. Asian J Androl 2016; 18:114-117.
24. AMS 700 with MS Pump Penile Prosthesis. Operating room manual. Boston scientific 2017. Online https://www.bostonscientific.com/content/dam/Manuals/us/current-rev-en/92127382-01B_AMS_700_ORM_en_s.pdf
25. Stember DS, Kohler TS, Morey AF. Management of perforation injuries during and following penile prosthesis surgery. J Sex med 2015 2015; 12:456-461.